Research Update · September 2026
A 2026 Review of Sunless Tanning: What It Says About Melanotan
A systematic review compared topical self-tanners, melanotan compounds and emerging approaches. Its most useful conclusion for melanotan readers is about the quality and limits of the evidence, not a new claim of proven safety or effectiveness.
What was reviewed?
In the February 2026 Journal of Clinical and Aesthetic Dermatology, Resnick and colleagues reviewed 68 peer-reviewed studies on sunless tanning molecules. Their scope included dihydroxyacetone (DHA), the active ingredient in many topical self-tanners, as well as melanotan compounds, forskolin and carotenoids. The authors examined mechanisms, possible clinical uses, formulations and adverse effects.
This was a review of existing publications, not a new clinical trial of Melanotan II. Combining different study types helps map a field, but it cannot fill gaps in long-term human safety data.
Different methods produce different kinds of color
DHA reacts with components in the outer skin layer to create a brown appearance. Melanocortin compounds act through a receptor pathway involved in melanin production. Carotenoids can give skin a yellow-orange hue, while much of the work on forskolin’s pigment effects has been in animals.
These mechanisms should not be treated as interchangeable. A visible color change does not by itself show that a product protects skin from ultraviolet radiation. Sun protection remains a separate question.
What the review says about melanotan safety
The review highlights published serious adverse-event reports linked to unregulated melanotan use and emphasizes that standardized reporting and long-term safety data are limited. Such reports show that serious events have been documented; they do not tell us how common an event is among all users, or prove the cause in every case.
Product identity also matters. The approved afamelanotide implant used for a specific medical condition has a defined formulation and clinical evidence. An online product labeled “Melanotan I” or “Melanotan II” should not be assumed equivalent to that prescription medicine. Our MT1 versus MT2 guide explains this distinction.
What remains uncertain
- Long-term outcomes after use of unapproved melanotan products have not been established by large, well-controlled human studies.
- Reports may mix different compounds, delivery routes, product quality and ultraviolet exposure.
- Data on less-studied sunless-tanning approaches are also limited, especially when findings come from cells or animals rather than people.
The review should therefore be read as a map of evidence and open questions. It does not validate a consumer tanning protocol, and it does not establish that all sunless options carry the same risks.
How this changes our coverage
We will continue to distinguish clinical research from anecdote, approved afamelanotide from unapproved products, and observed pigmentation from proven health benefit. Readers comparing methods can start with What Is Melanotan?, then review the human evidence and the safety questions.
Primary source
Reviewed September 2026. This article is educational information, not medical advice or a recommendation to use a tanning product.
